These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31729044)

  • 1. Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants.
    Malik PRV; Edginton AN
    J Clin Pharmacol; 2020 Apr; 60(4):466-476. PubMed ID: 31729044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.
    Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C
    Front Pharmacol; 2020; 11():868. PubMed ID: 32595502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.
    Hardiansyah D; Ng CM
    MAbs; 2018 Oct; 10(7):1144-1156. PubMed ID: 29969360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys.
    Li T; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):701-713. PubMed ID: 30423340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
    Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
    Xu Y; Langevin BA; Zhou H; Xu Z
    J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
    Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
    AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
    Garg A; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.
    Upreti VV; Wahlstrom JL
    J Clin Pharmacol; 2016 Mar; 56(3):266-83. PubMed ID: 26139104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients.
    Mahmood I; Tegenge MA
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S108-S116. PubMed ID: 34185903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.
    Hansen RJ; Balthasar JP
    J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
    Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
    Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model.
    Nakamura G; Ozeki K; Takesue H; Tabo M; Hosoya KI
    Biol Pharm Bull; 2021; 44(3):389-395. PubMed ID: 33642546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
    Li L; Gardner I; Dostalek M; Jamei M
    AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of models for predicting pediatric fraction unbound in plasma for human health risk assessment.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2021 Jan; 84(2):67-83. PubMed ID: 33106114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.